Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous mesoangioblast intra-arterial administration for m.3243A>G mitochondrial myopathy
NL-OMON59687Phase 2Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous mesoangioblasts in Mitochondrial myopathies (MM), sponsored by Maastricht University Medical Center+. Primary endpoints: Safety assessment, Muscle strength change and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
autologous mesoangioblasts
03
Conditions
Mitochondrial myopathies (MM)
Beyond the preview
Go deeper on NL-OMON59687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59687.